Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
MK-0524
HSMN NewsFeed - 20 Jun 2008
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
Biopharmaceuticals
HSMN NewsFeed - 28 Apr 2008
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
Biopharmaceuticals
FDA
HSMN NewsFeed - 29 Aug 2007
Merck Announces FDA Acceptance of NDA for CORDAPTIVE(TM) (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
Biopharmaceuticals
HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
HSMN NewsFeed - 15 Nov 2006
Merck's Investigational MK-0524 Significantly Reduced Flushing Caused By Extended-Release Niacin in Phase II Study
Biopharmaceuticals
HSMN NewsFeed - 29 Sep 2006
Merck Revises Regulatory Filing Timeline for MK-0524B, an Investigational Fixed-Dose Combination of MK-0524A and Simvastatin
Biopharmaceuticals
Cardiology
Return to NewsFeed
